Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Selumetinib Variants in Healthy Volunteers
NCT02322749Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of selumetinib in neurofibromatosis type 1 (NF1) (3 arms), sponsored by AstraZeneca. Primary endpoints: Maximum Plasma Concentration (Cmax) of Selumetinib, Area Under the Curve (AUC) of Selumetinib and 1 more. Started Feb 2015; status: completed.
02
Drugs
selumetinib
03
Conditions
neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on NCT02322749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02322749.